Latest News

Acalabrutinib With Axi-Cel Shows Promising Responses in R/R B-Cell Lymphoma
Acalabrutinib With Axi-Cel Shows Promising Responses in R/R B-Cell Lymphoma

February 23rd 2024

Acalabrutinib added to axicabtagene ciloleucel treatment was well-tolerated in patients with relapsed/refractory B-cell lymphoma.

What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL

February 16th 2024

Denileukin Diftitox BLA Resubmitted for CTCL After Addressing FDA Concerns
Denileukin Diftitox BLA Resubmitted for CTCL After Addressing FDA Concerns

February 14th 2024

Soquelitinib Receives FDA Orphan Drug Designation for T-Cell Lymphomas
Soquelitinib Receives FDA Orphan Drug Designation for T-Cell Lymphomas

February 12th 2024

Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL
Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL

February 7th 2024

Video Series
Video Interviews
Podcasts

More News